Bradesco backs Grupo Fleury in $13 million Brazil oncology push

Global investors holding shares of major Latin American financial institutions are seeing a new consolidation wave in private healthcare. On November 10, 2026, Brazilian banking giant Banco Bradesco—a staple in many emerging-market portfolios—announced a major joint venture with medical diagnostics leader Grupo Fleury to build a dedicated outpatient cancer care network.

The two companies signed a binding memorandum of understanding to invest 72 million reais (approximately $13 million) through 2027 to launch a new joint venture named FleuryOnco. Grupo Fleury will hold a 50.1% controlling stake and manage the medical, operational, and commercial activities of the business. Atlântica Hospitais, the healthcare infrastructure arm of Bradesco's insurance division Bradsaúde, will hold the remaining 49.9%.

The partnership plans to open seven specialized oncology clinics by 2027, focusing on the high-demand metropolitan hubs of São Paulo and Rio de Janeiro. The clinics will operate under two distinct brands: Fleury Oncologia, targeting the premium market in São Paulo, and OncoOne, which will serve both premium and mid-market patients across both states. Services will range from diagnostics and specialist consultations to chemotherapy, immunotherapy, and multidisciplinary support.

Diversifying Beyond Diagnostics

For Grupo Fleury, the move represents a deliberate pivot to capture a larger share of Brazil's rapidly growing oncology market. According to estimates from both companies published on November 10, 2026, cancer treatment revenues in Brazil are projected to reach 60 billion reais ($10.8 billion) this year, with outpatient services accounting for roughly 70% of that total.

The joint venture comes seven months after Fleury walked away from a potential 1 billion reais investment in Oncoclínicas, one of Brazil's largest cancer care operators. Instead of acquiring an existing player, Fleury is leveraging its long-standing relationship with Bradesco—which indirectly owns a 25% stake in the laboratory group—to build its own footprint from scratch.

While the initial $13 million investment is relatively small for both corporate giants, the venture is designed to scale quickly. The clinics will directly serve Bradsaúde's 4.1 million insured members but will also negotiate contracts with other private health insurance providers to maximize patient volume. The transaction is currently pending regulatory approval from Brazil's antitrust authority, CADE.

In your brokerage app

For retail investors, Grupo Fleury's primary shares are traded on the Brazilian B3 exchange under the ticker FLRY3. However, US-based investors can gain exposure to this healthcare expansion through Banco Bradesco S.A., which is listed in New York as an American Depositary Receipt (ADR) under the ticker BBDC. Bradesco's insurance and health division, Bradsaúde, is a primary driver of the bank's consolidated earnings and directly funds the Atlântica Hospitais venture.